Skip to main content
Figure 6 | Stem Cell Research & Therapy

Figure 6

From: A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement

Figure 6

Pluripotent-derived mesenchymal stem cells supplemented with platelet lysate are similar to other mesenchymal stem cells and different to pluripotent stem cells. (A) mRNA levels of extracellular matrix components in human foreskin fibroblasts (fib), induced pluripotent stem cells (iPS), PD-MSCPL, PD-MSCFBS and umbilical cord mesenchymal stem cells (UC-MSC). (B) Expression of mesenchymal stem cell markers in the indicated cell lines. Red, stained cells; black, unstained control. (C) Demethylation levels in all cell lines. Each square represents a CpG. Numbers indicate base positions relative to the transcription start site and delimit a CpG island. Globally, the OCT-4 promoter region was found demethylated in human embryonic stem cells (hES) and iPS, whereas all of the mesenchymal stem cells and fibroblasts showed it mostly methylated. FBS, fetal bovine serum; PD-MSCFBS, pluripotent-derived mesenchymal stem cells supplemented with fetal bovine serum; PD-MSCPL, pluripotent-derived mesenchymal stem cells supplemented with platelet lysate; PL, platelet lysate.

Back to article page